Literature DB >> 17602121

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

Paul Mackin1, David Bishop, Helen Watkinson, Peter Gallagher, I Nicol Ferrier.   

Abstract

BACKGROUND: Prevalence of physical comorbidity in severe mental illness is a significant public health concern, but comparative data in people with diagnoses other than schizophrenia are sparse. AIMS: To investigate the prevalence of metabolic disease and cardiovascular risk in people with severe mental illness treated with antipsychotics in the community.
METHODS: Case-control study of 90 people treated with antipsychotics in the community and 92 age- and gender-matched controls. The prevalence of metabolic syndrome and 10-year cardiovascular risk were calculated.
RESULTS: People on antipsychotics had a significantly worse metabolic profile than controls (F=6.583, d.f.=15,161, P<0.0001). Moreover, metabolic syndrome was more prevalent (OR=3.68, 95% CI 1.71-7.93, P=0.001), as was cardiovascular risk across a number of outcomes. These results are consistent across diagnostic groups.
CONCLUSIONS: People with severe mental illness treated with antipsychotics have excess metabolic dysfunction and heightened risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602121     DOI: 10.1192/bjp.bp.106.031716

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  23 in total

1.  Non-psychiatric health problems among psychiatric inpatients with intellectual disabilities.

Authors:  L Charlot; S Abend; P Ravin; K Mastis; A Hunt; C Deutsch
Journal:  J Intellect Disabil Res       Date:  2011-02

2.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

3.  Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.

Authors:  Andreas Windemuth; Jose de Leon; John W Goethe; Harold I Schwartz; Stephen Woolley; Margaret Susce; Mohan Kocherla; Kali Bogaard; Theodore R Holford; Richard L Seip; Gualberto Ruaño
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-08-06       Impact factor: 5.067

Review 4.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

5.  Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.

Authors:  David P J Osborn; Irwin Nazareth; Christine A Wright; Michael B King
Journal:  BMC Health Serv Res       Date:  2010-03-10       Impact factor: 2.655

6.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

7.  The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

8.  Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

Authors:  Deanna L Kelly; Robert P McMahon; Fang Liu; Raymond C Love; Heidi J Wehring; Joo-Cheol Shim; Kimberly R Warren; Robert R Conley
Journal:  J Clin Psychiatry       Date:  2010-01-12       Impact factor: 4.384

9.  Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Authors:  Virginia L Stauffer; Jennifer L Sniadecki; Kevin W Piezer; Jennifer Gatz; Sara Kollack-Walker; Vicki Poole Hoffmann; Robert Conley; Todd Durell
Journal:  BMC Psychiatry       Date:  2010-11-03       Impact factor: 3.630

10.  Neuropsychology of Bipolar Disorder.

Authors:  Peter Gallagher
Journal:  Curr Top Behav Neurosci       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.